EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 148 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 0.35 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $508,000 | -10.2% | 11,435 | 0.0% | 0.02% | +4.3% |
| Q1 2022 | $566,000 | -28.1% | 11,435 | -26.0% | 0.02% | -17.9% |
| Q4 2021 | $787,000 | -34.7% | 15,455 | -28.5% | 0.03% | -26.3% |
| Q3 2021 | $1,206,000 | +14.2% | 21,617 | -12.4% | 0.04% | +52.0% |
| Q2 2021 | $1,056,000 | +15.4% | 24,673 | +36.1% | 0.02% | +19.0% |
| Q1 2019 | $915,000 | +25.3% | 18,131 | 0.0% | 0.02% | +16.7% |
| Q4 2018 | $730,000 | +93.6% | 18,131 | +233.5% | 0.02% | +125.0% |
| Q3 2018 | $377,000 | -8.3% | 5,436 | 0.0% | 0.01% | -20.0% |
| Q2 2018 | $411,000 | +43.7% | 5,436 | 0.0% | 0.01% | +42.9% |
| Q1 2018 | $286,000 | -64.6% | 5,436 | -64.1% | 0.01% | -63.2% |
| Q4 2017 | $809,000 | +21.1% | 15,135 | +78.8% | 0.02% | +26.7% |
| Q2 2017 | $668,000 | +97.1% | 8,465 | +107.2% | 0.02% | +87.5% |
| Q1 2017 | $339,000 | +4.6% | 4,085 | 0.0% | 0.01% | +14.3% |
| Q4 2016 | $324,000 | – | 4,085 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JW Asset Management, LLC | 475,755 | $25,068,000 | 24.71% |
| Hudson Executive Capital LP | 971,000 | $51,162,000 | 15.09% |
| Park West Asset Management LLC | 1,051,274 | $55,392,000 | 2.47% |
| U S GLOBAL INVESTORS INC | 19,200 | $1,012,000 | 0.62% |
| Capital Impact Advisors, LLC | 26,317 | $1,387,000 | 0.57% |
| CLARK ESTATES INC/NY | 56,278 | $2,965,000 | 0.47% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 873,131 | $46,005,000 | 0.41% |
| ProQuest Associates IV LLC | 6,777 | $357,000 | 0.41% |
| Granite Investment Partners, LLC | 114,207 | $6,017,000 | 0.40% |
| GLOBEFLEX CAPITAL L P | 30,900 | $1,628,000 | 0.34% |